Sanofi
Insulin glargine/lixisenatide fixed ratio formulation
Last updated:
Abstract:
The present invention refers to a pharmaceutical composition comprising (a) lixisenatide or/and a pharmaceutically acceptable salt thereof, and (b) insulin glargine or/and a pharmaceutically acceptable salt thereof, wherein the compound (b) and compound (a) are present in a fixed ratio.
Status:
Grant
Type:
Utility
Filling date:
3 Apr 2019
Issue date:
8 Jun 2021